Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia

BACKGROUND: 5-α reductase inhibitors (5-ARIs) are first-line drugs for managing benign prostatic hyperplasia (BPH). Unfortunately, some patients do not respond to 5-ARI therapy and may even show worsening symptoms. The decreased expression of steroid 5-α reductase type 2(SRD5A2) in BPH tissues may e...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhanliang, Lin, Zhemin, Cao, Fang, Jiang, Mingxin, jin, Song, Cui, Yun, Niu, YN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639318/
https://www.ncbi.nlm.nih.gov/pubmed/36344974
http://dx.doi.org/10.1186/s12894-022-01121-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639318/
https://www.ncbi.nlm.nih.gov/pubmed/36344974
http://dx.doi.org/10.1186/s12894-022-01121-5

Ejemplares similares